Ryan Haumschild, PharmD, MS, MBA
Articles by Ryan Haumschild, PharmD, MS, MBA
Introduction: Risk Factors and Characteristics Defining SCLC
ByRyan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD ,Afshin Dowlati, MD ,Jacob Sands, MD ,Wade Iams, MD Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.
Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.
Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.
Guiding Patients Through Third-Line mCRC Therapy Decisions
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.
Patient Feedback for MDS: Insights and Closing Remarks
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer their insights and closing remarks regarding patient feedback for MDS.
Oral vs. IV HMAs: Considerations and Patient Guidance
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss considerations and patient guidance for oral and IV HMAs.
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.
Fruquintinib in mCRC: Key Insights From FRESCO-2
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.
Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
Innovations and Future Directions in Higher Risk MDS Treatments
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Real-World Impact of SUNLIGHT Outcomes in mCRC
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.
Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
ByRyan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD ,Michael Morse, MD, MHS, FACP,Ryan Huey, MD, MS Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.
HMA Persistence and Effectiveness in Higher Risk MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss the data gathered from the ASCERTAIN trial.
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts offer insights on the COMMANDS trial findings.
Choosing MDS Therapies: Risk-Based Approaches
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca Medical experts discuss risk-based approaches to choosing MDS therapies.
Advances in MDS Classification and Molecular Understanding
ByRyan Haumschild, PharmD, MS, MBA,James McCloskey, MD ,Amer Zeidan, MD,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Tracey Iraca After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
The Inflation Reduction Act: Implications for Patient Access in CL
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A group of experts discuss implications for patient access in CLL.
Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts discuss navigating access challenges in CLL treatment.
Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss financial challenges of BTK inhibitor therapy.
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of experts discuss combination regimens with BTK inhibitors.
Key Takeaways on RSV Vaccination
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.
Improving RSV Vaccination Rates and Addressing Misinformation
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.
Improving Insurance Coverage for RSV Vaccines
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Decision-Making in CLL: The Role of Real-World Evidence
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A discussion on therapeutic decision-making in CLL and the role of real-world evidence.
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
ByRyan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Current and Potential Obstacles Related to Administering RSV Vaccines
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.
Identifying Patients Eligible for RSV Vaccine
ByRyan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA,Marty J. Feltner, PharmD,Mary Bridgeman, PharmD, BCPS, BCGP,Abby Lynne Singleton, PharmD Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.
